Secondary Prevention of Atherothrombotic Events After Ischemic Stroke

Secondary prevention of atherothrombotic events after ischemic stroke.

Atherosclerotic vascular disease is the leading cause of ischemic stroke, resulting in occlusive or severely stenotic lesions of major intracranial or extracranial arteries and narrowing of small penetrating arteries of the brain. Atherosclerosis of the coronary arteries (ie, coronary artery disease) is an indirect cause of cardioembolic stroke secondary to myocardial infarction. Ischemic heart...

Secondary prevention of atherothrombotic or cryptogenic stroke.

Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke

Platelet antiaggregants in primary and secondary prevention of atherothrombotic events.

Atherothrombosis and its complications are currently the leading cause of worldwide mortality and its incidence is increasing . Platelets play an essential role in the pathogenesis of atherothrombotic events, justifying the use of antiplatelet agents in their prevention. Thus, it is essential to know the efficacy and safety profile of these drugs in primary and secondary prevention of atherothr...

Eicosapentaenoic Acid as long-term secondary prevention after ischemic stroke

BACKGROUND It is sometimes difficult to choose anti-thrombotic agents for secondary prevention in stroke patients at high bleeding risk. Recently, Eicosapentaenoic Acid (EPA) was reported to reduce the recurrence of stroke in hypercholesterolemic patients without increasing hemorrhagic risk. In this study, we investigated the features of recurrent stroke patients during EPA medication as second...